Abstracts 2016
1. Ionova T. Quality of Life and Symptom Burden in Myelofibrosis Patients: A Real World Study / T. Ionova, L. Anchukova, O. Vinogradova, T. Gritsenko, A. Evseev, L. Kozlova, K. Kurbatova, G. Kuchma, E. Lomaia, A. Lyamkina, E. Machulaytene, A. Myasnikov, T. Nikitina, M. Pankrashkina, T. Pospelova, A. Rodionova, E. Usacheva // Haematologica. 2016; Vol. 101 (Suppl 1): 810.
2. Salek S. The impact of hematological malignancy onpatients' health-related quality of life and symptoms: A qualitative study / S. Salek, P. Goswami, R. Else, E. Oliva, T. Ionova // Haematologica. 2016; Vol. 101 (Suppl. 1): 598.
3. Ionova T. Treatment adherence in patients with diabetes mellitus receiving oral combination therapy: data of a real-world study / T. Ionova, T. Nikitina, K. Kurbatova, A. Rodionova // Quality of Life Research. 2016; 25 (Suppl. 1): 131.
4. Ionova T. Applicability of the new instrument for symptom assessment in patients with myelofibrosis: real-world data / T. Ionova, K. Kurbatova, T. Nikitina, A. Rodionova // Quality of Life Research. 2016; 25 (Suppl. 1): 74-75.
5. Nikitina T.P. Potential prognostic value of quality of life in patients with chronic myeloid leukemia / T.P. Nikitina, T.I. Ionova, T.A. Gritsenko, L.K. Kozlova, K.A. Kurbatova, G.B. Kuchma, E.G. Lomaia, E.R. Machulaytene, N.V. Novitskaya, T.V. Shnaider, I.V. Sannikova, E.I. Usacheva // Quality of Life Research. 2016; 25 (Suppl. 1): 120.
6. Ionova T. Quality of life indicators and symptoms in patients with chronic myelogenous leukemia in the chronic phase (CP CML) with first and second dasatinib therapy in real clinical practice / T.I. Ionova, N.B. Bulieva, O.Y. Vinogradova, T.A. Gritsenko, Л.К. Козлова L.K. Kozlova, K.A. Kurbatova, G.B. Kuchma, E.G. Lomaia, E.R. Machulaytene, T.P. Nikitina, Н. N.V. Novitskaya, A.Y. Rodionova, E.I. Usacheva, T.V. Shnaider // EAFO. Clinical Hematology. 2016. Vol. 9 (3): 348. (In Russian)
7. Salek S.M. Quality of life issues relevant for patients with malignant blood diseases / S.M. Salek, E.N. Oliva, T.I. Ionova // EAFO. Clinical Hematology. 2016. Vol. 9 (3): 361. (In Russian)
8. Ionova T.I. Quality of life and symptoms in patients with myelofibrosis during the treatment: Data of clinical practice / T.I. Ionova, L.V. Anchukova, O.Yu. Vinogradova, T.A. Gritsenko, A.V. Evseev, L.K. Kozlova, K.A. Kurbatova, G.B. Kuchma, E.G. Lomaia, A.S. Lyamkina, E.R. Machulaytene, A.A. Myasnikov, T.P. Nikitina, M.M. Pankrashkina, T.I. Pospelova, A.Yu. Rodionova, E.I. Usacheva // Hematology and Transfusiology. 2016; 61 (1, suppl. 1): 122. (In Russian)
9. Ionova T.I. The use of dasatinib as the first line of therapy in patients in the chronic phase of chronic myelogenous leukemia (CML CML): clinical data and quality of life of patients in conditions of actual clinical practice / T.I. Ionova, N.B.Bulieva, K.A. Kurbatova, E.G. Lomaia, T.P. Nikitina, N.V. Novitskaya, A.Yu. Rodionova, E.I. Usacheva, M.M. Chukavina, M.V. Schumkova // Hematology and Transfusiology. 2016; 61 (1, suppl. 1): 122. (In Russian)
10. Ionova T. Quality of Life (QOL) and Health Utility (UT) in Patients with Type 2 Diabetes Mellitus (DM2) Receiving Different Oral Hypoglycemic / T. Ionova, T. Nikitina, A. Rodionova, K. Kurbatova // Therapy in a Real-World Setting. Value in Health. 2016; Volume 19 (Issue 7): A678
|
